Market Intelligence, Clinical Progress, and High-Purity Reagents for PDE5A-Targeted Therapeutics in Erectile Dysfunction, Pulmonary Arterial Hypertension, and Emerging Indications.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PDE5A drug discovery, covering all modalities and selectivity needs.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Catalytic Domain (535–860 aa) | PDE5A catalytic domain, HEK293 expressed. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View PDE5A Products |
| Full-Length Protein (with GAF-A/B) | PDE5A full-length containing regulatory domains for allosteric inhibitor screening. Theoretical MW verified. | View PDE5A Products |
| Gene Delivery | PDE5A Promise-ORF / Lentivirus premade particles for stable cell line generation. | View PDE5A Products |
| Benchmark Antibody | Anti-PDE5A monoclonal antibody (research grade) for Western blot/IHC validation. | View PDE5A Products |
| Validator | PDE5A siRNA Set for specific knockdown and target validation. | View PDE5A Products |
| Off-Target Control A | PDE6 (α′/γ subunits) and PDE11A recombinant proteins – critical counter-screens for visual and muscle side effects. | View PDE6 Products / View PDE11 Products |
| Off-Target Control B | PDE9A recombinant protein – cGMP-specific PDE for CNS/cardiology selectivity panels. | View PDE9A Products |
| Synergistic Target | sGC (Soluble Guanylate Cyclase) recombinant protein – upstream cGMP pathway node for combination studies. | View sGC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PDE Family Selectivity (PDE6/PDE11/PDE9) | Homolog panel proteins strictly Sequence Verified by mass spec, >95% purity for accurate IC50 determination. |
| Allosteric vs Active Site Inhibition | Full-length PDE5A with intact GAF domains vs truncated catalytic domain available for differential binding assays (SPR, ITC). |
| Isoform Specificity (PDE5A1 vs A2 vs A3) | N-terminally distinct recombinant isoforms; theoretical MW confirmed. |
| High-Throughput cGMP Hydrolysis Assay | High-specific-activity enzyme preparation with defined specific activity units. |
| Cellular Target Engagement / False Positives | Lentivirus stable cell lines for cGMP reporter assays; validated siRNA + Rescue ORF for specificity control. |
Live PDE5A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The PDE5A inhibitor landscape is transitioning from first-generation blockbusters (sildenafil, tadalafil, vardenafil, avanafil) – now fully genericized – to precision selectivity and repurposing. While erectile dysfunction (ED) and pulmonary arterial hypertension (PAH) remain core markets, next-generation R&D focuses on:
- Heart failure with preserved ejection fraction (HFpEF)
- Immuno-oncology modulation (PDE5 inhibition reduces MDSC immunosuppression, enhancing PD-1/PD-L1 therapy)
- Neurodegenerative diseases (improving cerebral microcirculation)
- Benign prostatic hyperplasia / lower urinary tract symptoms (BPH-LUTS)
The next wave targets allosteric modulators, isoform-selective inhibitors (PDE5A1 vs PDE5A2), and PROTAC degraders to overcome off-target liabilities against photoreceptor PDE6 and skeletal muscle PDE11.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Orthosteric) | Pfizer, Eli Lilly, Bayer | ED, PAH, BPH | Enzymatic activity assay; high-purity catalytic domain protein |
| Small Molecule (Allosteric) | Preclinical Biotech | HFpEF, Oncology | Full-length PDE5A with GAF domains for binding studies |
| PROTAC / Degrader | Emerging Academic/Biotech | Refractory PAH, Oncology | Cell-based target engagement; Lentivirus stable lines |
| Combination (PDE5i + sGC stimulator) | Molecular Partners | Cardiovascular | Pathway proteins (sGC + PDE5A co-assay) |
| Fixed-Dose Combination | Various (e.g., PDE5i + SSRI or ARB) | ED + BPH-LUTS | Cell-based cGMP assay; stable overexpression line |
| Repurposing / Immuno-oncology | Academic / Biotech (preclinical) | Solid Tumors (MDSC modulation) | T-cell suppression assay; Lentivirus stable cell line |
Molecular Differentiation & Assay Strategy
Key differentiation axes for best-in-class PDE5A inhibitors:
- Selectivity: PDE6 (vision) and PDE11 (myalgia) cross-reactivity must be avoided. Required >100-fold selectivity over PDE6α'/γ and PDE11A4.
- Mechanism: Allosteric inhibitors (binding GAF-B domain) enable NO-independent activation, beneficial in endothelial dysfunction.
- Isoform selectivity: PDE5A1 (ubiquitous), PDE5A2 (lung/penis high), PDE5A3 (splice variant) – differential N-termini require distinct constructs.
- PK/PD: Long-acting tadalafil vs short-acting sildenafil; Koff kinetics matter.
Recommended assay cascade:
- Enzymatic inhibition IC50 using high-purity catalytic domain (cGMP hydrolysis).
- Selectivity panel with PDE6, PDE11, PDE9, PDE1.
- Binding kinetics (SPR) using full-length or catalytic domain.
- Cellular cGMP reporter assay with PDE5A-overexpressing stable cells.
- siRNA knockdown to confirm on-target effect.
TarMart offers all reagents needed for this cascade, including cross-species orthologs (human/mouse/cyno) for toxicology bridging.
Related Targets for Cross-Sell
- PDE6 – Off-target for vision safety; recommended for selectivity screening.
- PDE11A – Off-target for muscle toxicity; recommended with PDE5A as a panel.
- PDE9A – CNS/cardiology cGMP-specific PDE; synergistic for pathway-wide studies.
- sGC (GUCY1A2/GUCY1B3) – Upstream cGMP synthesis; combination partner in HFpEF and PAH.